Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020
I'm PortAI, I can summarize articles.
Lexeo Therapeutics, Inc. announced positive interim data from its Phase I/II trial of LX2020 for PKP2-associated arrhythmogenic cardiomyopathy. The treatment was well tolerated with no significant complement activation in 10 participants. Mean PKP2 protein expression increased by 93% in the low-dose and 162% in the high-dose cohorts. Most participants experienced stabilization or improvement in arrhythmia burden, with a 22% mean improvement in non-sustained ventricular tachycardia in the high-dose cohort. Regulatory engagement is expected in 2026 after enrollment completion in Q4 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments